Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium
Press release:
Monday December 10, 6:00 am ET
Scientific Presentations Detail Progress with VeraTag(TM) Assays in Breast Cancer
SOUTH SAN FRANCISCO, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM - News) today announced five posters to be presented at the 30th San Antonio Breast Cancer Symposium taking place in San Antonio, TX, from December 13 - 16, 2007. Following are details for each embargoed session:
-- Friday, December 14th, 2007, 7.00 am - 9.00 am CST
Abstract # 2007: Quantitative measurements of HER2 expression and HER2:HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment. (Presenter: W. Huang)
-- Friday, December 14th, 2007, 7.00 am - 9.00 am CST
Abstract # 2011: Development of novel proximity-based immunoassays for the detection of HER heterodimerization in breast cancer cell line lysates and formalin-fixed, paraffin-embedded tissue. (Presenter: L. Eli)
-- Friday, December 14th, 2007, 7.00 am - 9.00 am CST
Abstract # 2012: Characterization of a novel proximity immunoassay for the quantitative determination of HER2 protein expression and HER2 homodimerization in formalin-fixed, paraffin-embedded breast cancer tissue. (Presenter: J. Winslow)
-- Saturday, December 15th, 2007, 7.00 am - 9.00 am CST
Abstract # 4108: Profiling HER-family receptor dimerization in HER2 over expressing cells that co-express mutated EGFR receptors. (Presenter: R. Dua)
-- Saturday, December 15th, 2007, 5.00 pm - 7.00 pm CST
Abstract # 5002: Increased detection of breast cancer markers human epidermal growth factor receptor dimer and downstream signaling proteins utilizing the VeraTag technology with dextran modified antibodies. (Presenter: J. Wallweber)
About HERmark(TM)
HERmark is a propriety diagnostic that accurately quantifies HER2 expression and dimerization in patients with breast cancer. Preliminary data from three cohorts of trastuzumab-treated patients with metastatic breast cancer who were identified as "HER2 positive" by conventional assays suggest that HERMark can identify patients who are likely to respond to Herceptin with greater precision than currently available tests, permitting stratification of patients according to their degree of clinical benefit from the drug. Additional studies of HERmark for breast cancer in both the metastatic and adjuvant settings are in progress.
About VeraTag(TM)
VeraTag is a proximity-based assay technology platform that accurately quantifies proteins and functional protein complexes. This platform provides a researcher or clinician a more thorough understanding of protein-protein interactions or signaling pathway activity allowing for disease characterization at the molecular level. VeraTag is designed to run on standard formalin-fixed paraffin embedded (FFPE) patient samples.
About Monogram
Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at www.monogrambio.com.
VeraTag and HERmark are trademarks of Monogram Biosciences, Inc.
Contacts:
Alfred G. Merriweather
Chief Financial Officer
Tel: 650 624 4576
amerriweather@monogrambio.com
Jeremiah Hall
Feinstein Kean Healthcare
Tel: 415 677 2700
jeremiah.hall@fkhealth.com
--------------------------------------------------------------------------------
Source: Monogram Biosciences, Inc.
